Seat sharing deal for LS polls in Karnataka: Cong likely to field 18-20 candidates; JD(S) 8-10

coastaldigest.com web desk

July 8, 2018

Bengaluru, Jul 8: The Indian National Congress is likely to get opportunity to contest at least two-third of total Lok Sabha seats in Karnataka following a seat-sharing agreement with Janata Dal (Secular) in upcoming general elections.

There are 28 Lok Sabha constituencies in Karnataka, and the Congress contested in all in 2014 and won nine seats, while the BJP won 17 and the JD(S) two. In the 2009 general elections, the BJP secured 19 seats, Congress six, and JD(S) three.

According to sources, the formula adopted for allocation of Cabinet berths in the coalition government in the state is expected to be used in chalking out a seat-sharing deal between the two parties. During the allocation of Cabinet berths, the Congress was given two-thirds (22) of the 34 berths.

Senior Congress leader and former Union Minister M Veerappa Moily, said that the two parties are expected to enter into an alliance for the 2019 elections and the Congress would contest in 18-20 constituencies, leaving 8-10 seats for the JD(S).

Moily did not name the constituencies where the JD(S) would field its candidates. He said an agreement on contesting the general elections jointly has been reached between the two parties. “We will continue the same formula adopted for sharing Cabinet berths,” he said. In the next few months, the party’s central leadership would take a final call on the exact number of seats to be shared, he added.

Comments

HDK may start issues again.

HDK, cong making you fool. JDS should get majority

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

Pass mandatory for vehicles to ferry fruits, vegetables from Dakshina Kannada to Kasaragod

coastaldigest.com news network

July 8,2020

Kasaragod, Jul 8: The meeting of Kasaragod district-level corona control core committee has resolved to make pass mandatory for vehicles to bring vegetables and fruits to Kasaragod from Dakshina Kannada and other parts of Karnataka.

Pass will be issued by RTO. Employees, including the driver of the vehicle, must visit the nearest primary health facility once in seven days and undergo a health check and submit a medical officer's certificate.

District Collector Dr D Sajith Babu, who presided over the meeting, said that only those vegetable and fruit vehicles that produce medical officer's certificate and RTO's passes will be allowed to cross the border.

Meeting, the RTO has decided to convene an emergency meeting of vegetable and fruit merchants.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

USA buys up world’s stock of key covid drug; no other country can now buy remdesivir

coastaldigest.com web desk

July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19.

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar.

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease.

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments